Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
J Gerontol B Psychol Sci Soc Sci. 2024 Aug 1;79(8). doi: 10.1093/geronb/gbae109.
Early diagnosis of Alzheimer's disease (AD) using brain scans and other biomarker tests will be essential to increasing the benefits of emerging disease-modifying therapies, but AD biomarkers may have unintended negative consequences on stigma. We examined how a brain scan result affects AD diagnosis confidence and AD stigma.
The study used a vignette-based experiment with a 2 × 2 × 3 factorial design of main effects: a brain scan result as positive or negative, treatment availability and symptom stage. We sampled 1,283 adults ages 65 and older between June 11and July 3, 2019. Participants (1) rated their confidence in an AD diagnosis in each of four medical evaluations that varied in number and type of diagnostic tools and (2) read a vignette about a fictional patient with varied characteristics before completing the Modified Family Stigma in Alzheimer's Disease Scale (FS-ADS). We examined mean diagnosis confidence by medical evaluation type. We conducted between-group comparisons of diagnosis confidence and FS-ADS scores in the positive versus negative brain scan result conditions and, in the positive condition, by symptom stage and treatment availability.
A positive versus negative test result corresponds with higher confidence in an AD diagnosis independent of medical evaluation type (all p < .001). A positive result correlates with stronger reactions on 6 of 7 FS-ADS domains (all p < .001).
A positive biomarker result heightens AD diagnosis confidence but also correlates with more AD stigma. Our findings inform strategies to promote early diagnosis and clinical discussions with individuals undergoing AD biomarker testing.
使用脑部扫描和其他生物标志物测试对阿尔茨海默病(AD)进行早期诊断对于提高新兴的疾病修饰疗法的益处至关重要,但 AD 生物标志物可能会对污名化产生意想不到的负面影响。我们研究了脑部扫描结果如何影响 AD 诊断信心和 AD 污名化。
该研究采用基于情景的实验,采用 2×2×3 的因子设计,主要影响因素包括:脑部扫描结果为阳性或阴性、治疗方法的可用性和症状阶段。我们于 2019 年 6 月 11 日至 7 月 3 日期间招募了 1283 名年龄在 65 岁及以上的成年人。参与者(1)在四种不同的医疗评估中,对 AD 诊断的信心进行了评分,这四种医疗评估在诊断工具的数量和类型上有所不同;(2)在完成《阿尔茨海默病修改后的家庭污名量表》(FS-ADS)之前,阅读了一个关于具有不同特征的虚构患者的情景描述。我们根据医疗评估类型检查了平均诊断信心。我们比较了阳性与阴性脑部扫描结果条件下的诊断信心和 FS-ADS 评分,在阳性结果条件下,我们还比较了不同症状阶段和治疗可用性下的诊断信心和 FS-ADS 评分。
阳性与阴性测试结果与 AD 诊断信心较高相关,而与医疗评估类型无关(均 p<0.001)。阳性结果与 FS-ADS 量表的 7 个领域中的 6 个领域的反应更强烈相关(均 p<0.001)。
阳性生物标志物结果提高了 AD 诊断信心,但也与 AD 污名化程度增加相关。我们的研究结果为促进 AD 早期诊断和与接受 AD 生物标志物测试的个体进行临床讨论的策略提供了信息。